|
Summary Information: Immunovant Inc. Common Stock NASDAQ:IMVT |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
__The following are links to various summary and news pages for __Immunovant Inc. Common Stock [ IMVT ]. __Note: Some Links might not have information for the company. |
|